JP2024517087A5 - - Google Patents

Info

Publication number
JP2024517087A5
JP2024517087A5 JP2023562610A JP2023562610A JP2024517087A5 JP 2024517087 A5 JP2024517087 A5 JP 2024517087A5 JP 2023562610 A JP2023562610 A JP 2023562610A JP 2023562610 A JP2023562610 A JP 2023562610A JP 2024517087 A5 JP2024517087 A5 JP 2024517087A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weekly
seq
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024354 external-priority patent/WO2022221239A1/en
Publication of JP2024517087A publication Critical patent/JP2024517087A/ja
Publication of JP2024517087A5 publication Critical patent/JP2024517087A5/ja
Pending legal-status Critical Current

Links

JP2023562610A 2021-04-12 2022-04-12 小児重症筋無力症を治療するための組成物及び方法 Pending JP2024517087A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US63/173,919 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US63/219,155 2021-07-07
US202263266880P 2022-01-18 2022-01-18
US63/266,880 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (2)

Publication Number Publication Date
JP2024517087A JP2024517087A (ja) 2024-04-19
JP2024517087A5 true JP2024517087A5 (cg-RX-API-DMAC7.html) 2025-04-22

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562610A Pending JP2024517087A (ja) 2021-04-12 2022-04-12 小児重症筋無力症を治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US20240182598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517087A (cg-RX-API-DMAC7.html)
KR (1) KR20230169207A (cg-RX-API-DMAC7.html)
AU (1) AU2022256389A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021046A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003033A1 (cg-RX-API-DMAC7.html)
IL (1) IL307445A (cg-RX-API-DMAC7.html)
JO (1) JOP20230247A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012032A (cg-RX-API-DMAC7.html)
PH (1) PH12023552841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
IL280280B2 (en) * 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) * 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法

Similar Documents

Publication Publication Date Title
JP2023548858A5 (cg-RX-API-DMAC7.html)
Milo Therapies for multiple sclerosis targeting B cells
CN103930444B (zh) 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
JP2017160208A5 (cg-RX-API-DMAC7.html)
CN111787981B (zh) 增加肌肉量和减少脂肪量的方法
JP2024102205A5 (cg-RX-API-DMAC7.html)
CN113195540A (zh) 提供皮下施用抗cd38抗体的方法
JP2018138551A (ja) 関節リウマチの治療
RU2013121156A (ru) Препарат антитела
JP2022515770A5 (cg-RX-API-DMAC7.html)
CN115427450A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN114344460B (zh) 含有抗pcsk9抗体的稳定制剂及其制备方法和用途
CN118105485B (zh) 一种稳定的抗人IL-4Rα单克隆抗体制剂
JP2025514142A5 (cg-RX-API-DMAC7.html)
WO2021100794A1 (ja) 抗体含有製剤
EP4387999A1 (en) Ofatumumab for treating pediatric ms
KR20250110257A (ko) Hgfr 및 egfr에 특이적으로 결합하는 이중특이성 항체를 포함하는 약학적 조성물
US20210393777A1 (en) Stable preparation comprising anti-pcsk9 antibody
US12139546B2 (en) Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
JP2023531722A5 (cg-RX-API-DMAC7.html)
JP2022527542A5 (cg-RX-API-DMAC7.html)
TW202442677A (zh) 用於治療自體免疫溶血性貧血(aiha)之方法及組成物
WO2020063668A1 (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
TW202404639A (zh) Aiha之治療
WO2023134771A1 (zh) 抗ctla-4抗体药物组合物及其用途